Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
15 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/15/3061736/0/en/Entera-Bio-s-EB613-Demonstrates-Early-Impact-on-Both-Trabecular-and-Cortical-Bone-Compartments-with-6-Months-of-Treatment-in-Post-Menopausal-Women-with-Osteoporosis-Highlighted-as-.html
19 Mar 2025
// BIOSPACE
https://www.biospace.com/business/opko-and-entera-link-up-to-advance-first-oral-glp-1-glucagon-drug-into-clinic
08 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/08/2977864/0/en/Entera-Bio-Reports-Q3-2024-Financial-Results-and-Provides-Business-Updates.html
01 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/01/2922775/0/en/Entera-s-EB613-the-First-Once-Daily-PTH-1-34-Tablet-Treatment-Dedicated-to-Post-Menopausal-Women-with-High-Risk-Osteoporosis-Abstract-Selected-for-Presentation-at-the-ASBMR-2024-An.html
03 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/03/2892199/0/en/Entera-Bio-Reports-Phase-1-Clinical-Data-of-First-in-Class-Oral-PTH-1-34-Peptide-Candidate-EB612-for-Patients-with-Hypoparathyroidism-at-ENDO-2024.html
20 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/03/20/2849325/0/en/Entera-Bio-Announces-Robust-Pharmacokinetic-Data-for-First-in-Class-Oral-GLP-2-Peptide-Tablet-Treatment-for-Patients-with-Short-Bowel-Syndrome.html
Details:
OXM is a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Lead Product(s): Oxyntomodulin Analog
Therapeutic Area: Nutrition and Weight Loss Brand Name: OXM
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: OPKO Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2024
Lead Product(s) : Oxyntomodulin Analog
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Entera and OPKO Share PK/PD Results for Oral GLP-1 Peptide Candidate for Obesity
Details : OXM is a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Product Name : OXM
Product Type : Peptide
Upfront Cash : Inapplicable
September 25, 2024
Details:
EB613 (teriparatide) is the first and most advanced oral, daily tablet formulation of synthetic hPTH (1-34), which is being evaluated for the treatment of osteoporosis.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Brand Name: EB613
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2024
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Entera Bio Announces Key Milestone for Oral PTH(1-34) Phase 3 Program with FDA Ruling
Details : EB613 (teriparatide) is the first and most advanced oral, daily tablet formulation of synthetic hPTH (1-34), which is being evaluated for the treatment of osteoporosis.
Product Name : EB613
Product Type : Peptide
Upfront Cash : Inapplicable
March 26, 2024
Details:
Entera Bio & Opko Health are developing the first GLP-2 peptide tablet alternative for short bowel syndrome and mucosal inflammation disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: OPKO Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : OPKO Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Entera Bio Reports Data for Oral GLP-2 Peptide Tablet in Short Bowel Syndrome
Details : Entera Bio & Opko Health are developing the first GLP-2 peptide tablet alternative for short bowel syndrome and mucosal inflammation disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 20, 2024
Details:
Under the collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs, including Teduglutide, the only approved GLP-2 analog, for the development of oral tablet formulations using Entera’s proprietary oral delivery technology.
Lead Product(s): Teduglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: OPKO Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 09, 2023
Lead Product(s) : Teduglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : OPKO Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs, including Teduglutide, the only approved GLP-2 analog, for the development of oral tablet formulations using Entera’s proprietary ora...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
December 09, 2023
Details:
EB613 (teriparatide) is first-in-class oral PTH(1-34) peptide biosimilar, which is being evaluated in phase 2 clinical trials for the treatment of Osteoporosis.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Brand Name: EB613
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2023
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EB613 (teriparatide) is first-in-class oral PTH(1-34) peptide biosimilar, which is being evaluated in phase 2 clinical trials for the treatment of Osteoporosis.
Product Name : EB613
Product Type : Peptide
Upfront Cash : Inapplicable
November 29, 2023
Details:
EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Brand Name: EB613
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2023
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis.
Product Name : EB613
Product Type : Peptide
Upfront Cash : Inapplicable
September 11, 2023
Details:
EB613 is the first oral, once daily mini tablet presentation of synthetic hPTH (1-34), (teriparatide), consisting of the exact same 34 amino acid sequence as daily subcutaneous teriparatide injection, Forteo®, which requires daily SC injections.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Brand Name: EB613
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2023
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
Details : EB613 is the first oral, once daily mini tablet presentation of synthetic hPTH (1-34), (teriparatide), consisting of the exact same 34 amino acid sequence as daily subcutaneous teriparatide injection, Forteo®, which requires daily SC injections.
Product Name : EB613
Product Type : Peptide
Upfront Cash : Inapplicable
March 04, 2023
Details:
EB613 (teriparatide) is an oral, daily tablet which stimulates new bone formation on trabecular and cortical bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity. It is being investigated for post-menopausal osteoporosis.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Brand Name: EB613
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2023
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal...
Details : EB613 (teriparatide) is an oral, daily tablet which stimulates new bone formation on trabecular and cortical bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity. It is being investigated for post-menopausal osteo...
Product Name : EB613
Product Type : Peptide
Upfront Cash : Inapplicable
February 15, 2023
Details:
EB613 is an oral formulation of synthetic hPTH (1-34 teriparatide), a peptide consisting of the first 34 amino acids of PTH which represent the functional region. Subcutaneous Forteo® (teriparatide injection) has been the leading anabolic treatment of osteoporosis since 2002.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Brand Name: EB613
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2022
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EB613 is an oral formulation of synthetic hPTH (1-34 teriparatide), a peptide consisting of the first 34 amino acids of PTH which represent the functional region. Subcutaneous Forteo® (teriparatide injection) has been the leading anabolic treatment of o...
Product Name : EB613
Product Type : Peptide
Upfront Cash : Inapplicable
December 09, 2022
Details:
EB613 is an oral formulation of synthetic hPTH (1-34), (teriparatide), a peptide consisting of the first 34 amino acids of PTH which represent the functional region.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Brand Name: EB613
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2022
Lead Product(s) : Teriparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EB613 is an oral formulation of synthetic hPTH (1-34), (teriparatide), a peptide consisting of the first 34 amino acids of PTH which represent the functional region.
Product Name : EB613
Product Type : Peptide
Upfront Cash : Inapplicable
July 26, 2022
ABOUT THIS PAGE